

Pralsetinib ARROW

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects




Other adjustments



Pralsetinib ARROW

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Endocrine Tumours
Therapeutic Indication: Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant MTC who require systemic therapy
Experimental Arm: Pralsetinib
Control Arm: Single arm

